Waters WAT
Healthcare · Medical - Diagnostics & Research · Synthos Deep Dive · 2026-07-03
The Overview
Waters makes the expensive, precise machines that labs use to measure what's in a sample — is this drug pure? is this water safe? what proteins are in this blood? Crucially, once a lab buys a Waters machine, it has to keep buying Waters' columns, chemicals, and service contracts for years — like a razor company that sells cheap razors and expensive blades. That makes the revenue very reliable.
In February 2026 Waters made its biggest move ever: it bought two businesses from Becton Dickinson (BD) — one in biosciences, one in diagnostics — that roughly double its sales to about $6.4 billion this year. That is exciting (more growth, new markets) but also risky (big acquisitions are hard to blend together, and Waters took on debt and issued stock to pay for it).
Is the stock cheap or expensive? About fair. You pay roughly $26 for every $1 of next year's earnings, and earnings are growing around 10-12% a year — a reasonable, not a bargain, price.
Our verdict is Watch: a genuinely good company, but there's no obvious edge to buying today. Here's what our three scores mean in everyday terms:
- Downside Risk 6/10 (a bit above average). The core business is steady, but the stock swings a little more than the market, it took on debt for the deal, and the merger could stumble.
- Growth Quality 6/10 (good, not great). Reliable and profitable, but it grows slowly and the growth is slowing further as the deal is absorbed.
- Exponential Potential 4/10 (low). This is a steady tortoise, not a rocket. Don't expect it to double quickly.
The one big worry: blending BD's businesses into Waters cleanly — if the integration goes badly, both the earnings and the debt get worse at once.
Putting a number on it: our fair-value estimate is $400 against a current price of $414.69 — a premium price for a business we still like.
Our summary metrics
Modest leverage post-BD deal & 26× forward — but integration risk, beta 1.2, and a Hold-rated Street.
~10-12% forward EPS CAGR, 55% gross margin, sticky consumables razor-blade model, but decelerating.
A quality instruments compounder, not an exponential — mid-single-digit organic growth, ~$31B cap, mature TAM.
What does “fair value” mean?
Fair value is Synthos’s estimate of what one share is worth today, based on our model of the company’s future cash generation and the risks to it. It is not a price target or a prediction of where the stock trades next quarter — it’s the price where we think risk and reward are balanced. Above it, you’re paying for outcomes better than our base case; below it, the market is offering a margin of safety.
The model’s inputs and weightings are proprietary — they’re the product. What we publish is the output, plus an independent, public-math cross-check further down the page (“Check our number”) so you can judge it for yourself.
What do the 5 tiers mean? (Core · Tactical · Watch · Hold · Avoid)
Exponential Potential
A quality instruments compounder, not an exponential — mid-single-digit organic growth, ~$31B cap, mature TAM.
What could take this further than the base case — and where the market may be underpricing it. Full forward-growth and acceleration math in Deeper analysis, §4 below.
Deeper analysis
Technicals, fundamentals, valuation, and the full expert-claim evidence panel — the detail behind the numbers above.
Reference table
| Street consensus | $395 (high $440 / low $350; 12 Buy · 20 Hold · 3 Sell → Hold) — context, not our anchor |
| Valuation | 48× trailing GAAP EPS · 26× FY26E · 23× FY27E · 18× FY30E · EV/S ~7.9× · EV/EBITDA ~15× (fwd) |
| Technicals | Mild uptrend — $379, −8% off 52-wk high, above 50/200-DMA (both ~$348), RSI 67, +6% 12-mo vs SPY +21% (a laggard) |
| Conviction | Low — 0 expert voices in the KB; call rests entirely on fundamentals, quant and management's own (half-weighted) guidance |
| Position sizing | If owned, a small ~1-2% quality-cyclical sleeve position; no urgency to act |
What the experts actually said
No independent expert claims in the Synthos knowledge base yet for WAT — this dive is fundamentals- and technicals-driven, not panel-driven.
Price & moving averages 12 months · 50 & 200-day averages · 52-week range
Solid line = price · dashed line = 50-day average · dotted line = 200-day average · the two thin horizontal lines mark the 52-week high and low. Price above both averages is an uptrend.
Data summary: last close $414.69, 7% above the 50-day average ($387), 15% above the 200-day average ($360) — an uptrend. 2% below the 52-week high of $421, 46% above the 52-week low of $283.
Bollinger Bands 20-day average ± 2 standard deviations
The shaded band widens when the stock gets more volatile. Riding the upper edge = strong momentum (sometimes stretched); the lower edge = weak / potentially oversold.
Data summary: price $414.69 is currently inside the band (band $388–$428).
RSI (14) momentum gauge · 0–100
Above 70 (overbought zone, shaded) = overbought, below 30 (oversold zone, shaded) = oversold. Currently 59.
MACD 12 / 26 / 9 · trend & momentum
The MACD line crossing above the signal line (bars flip to the up color) = momentum turning up; crossing below (bars flip to the down color) = turning down. Bar height = the size of that gap.
Data summary: MACD is currently below its signal line by 0.39, negative momentum.
Relative performance vs S&P 500 & its sector (XLV (sector)), set to 100 a year ago
Solid = WAT · dashed = S&P 500 · dotted = XLV (sector). A rising line means it is beating that benchmark — the sector line shows whether it is a leader or laggard within its own group.
Forward revenue & earnings actual → estimate · "FY" = fiscal year, "E" = estimate
Darker bars = actual results, brighter = analyst estimates. Taller bars to the right = expected growth.
Key stats an RIA wants
1. What it is
Waters Corporation (NYSE: WAT) is a ~$31B-market-cap global leader in specialized analytical measurement, founded 1958, headquartered in Milford, Massachusetts, run by CEO Udit Batra. The pre-2026 business had two segments:
- Waters — high- and ultra-performance liquid chromatography (LC) and mass spectrometry (MS) instruments, plus the high-margin razor-blades that ride on them: chromatography columns and chemistry consumables, software, and post-warranty service contracts.
- TA (now Materials Sciences Division) — thermal analysis, rheometry and calorimetry instruments.
The customer base is pharma/biotech (the biggest slice — drug QA/QC and development), plus food/nutritional safety, environmental testing, academic and industrial labs — regulated, high-volume, repeat-testing environments where switching costs are high.
The transformational change (§9 detail): On February 9, 2026 Waters closed its acquisition of BD's Biosciences and Diagnostic Solutions businesses (~$17.5B deal, part cash/debt, part stock — share count jumped from ~59.5M to ~82.1M). The company now reports through four divisions: Analytical Sciences (the old Waters core), Biosciences (WBD), Advanced Diagnostics (ADx), and Materials Sciences (MSD). This roughly doubles revenue to a guided ~$6.4B in FY26.
Revenue mix — pre-deal FY2025 (from FMP segmentation; the acquired units are not yet in annual segment data):
- By product: Waters Instrument Systems $1.10B · Waters Service $1.08B · Chemistry Consumables $631M · TA Instrument Systems $244M · TA Service $108M. Note the razor-blade quality: service + consumables ($1.82B) exceed instrument sales — a recurring, high-margin base.
- By geography (FY25): Americas $1.16B (37%) · Asia-Pacific $1.04B (33%) · Europe $963M (30%). Well-diversified geographically; China exposure (within APAC) is a swing factor for instrument demand.
2. The expert thesis — no coverage in the Synthos KB
There is no expert thesis to cite. total_claims for WAT in the Synthos knowledge base is 0 — zero net-bullish voices, zero cautionary voices, zero traceable claim_ids.
This is stated plainly and by design: Synthos does not fabricate conviction. Many high-quality S&P 500 names simply do not appear in the podcast/expert transcript corpus the KB is built from — analytical-instruments companies like Waters are under-covered by the macro/tech/biotech voices the KB tracks. The verdict, scores and fair value in this note are therefore entirely fundamentals-, quant- and guidance-driven, with management's own words half-weighted (§9). Where a conviction name like our Lilly note leans on 250+ reconciled claims, this note leans on the filings and the estimate sheet — and we flag that lower epistemic confidence honestly in the Low conviction rating.
3. Synthos scores & the Bull / Base / Bear cases
The one-glance judgment — three scores, 0–10, each anchored to real metrics (not probabilities we can't honestly calibrate):
| Score | 0–10 | The read |
|---|---|---|
| Downside Risk (lower = safer) | 6 · Moderate | Sticky recurring revenue and 55% gross margin cushion the downside, but the BD deal lifted leverage (TTM net-debt/EBITDA ~5.5× on the transaction-loaded metric; core pre-deal was ~0.9×), beta is 1.2, instruments are cyclical, and a Hold-rated Street with a 48× trailing multiple leaves little slack. |
| Growth Quality | 6 · Good | ~10-12% forward EPS CAGR, 55% gross margin, elite razor-blade recurring mix, high returns on tangible capital — but organic growth is only mid-single-digit and the acquisition (not organic engine) drives the near-term step-up. |
| Exponential Potential | 4 · Low-Moderate | A durable compounder past any acceleration. Guidance is for ~6.5-8% organic constant-currency growth; the analytical-instruments TAM is mature; at ~$31B cap with mid-single-digit organic growth this is a tortoise, not a multibagger. |
The three cases (our own scenario model — assumptions shown; each target is a ~12–18-month fair value). We deliberately do not attach probabilities: the base case is by definition the expected path, so a weighted blend would just restate it with false precision. The cases bound the range; the scores above summarize them.
| Case | Key assumptions | Fair value |
|---|---|---|
| Bull | BD integration goes clean; revenue synergies compound; instrument replacement cycle + new launches sustain double-digit adjusted EPS growth. FY27E EPS beats to ~$17.5 (vs $16.46 cons); market pays up to ~28× for a re-rated growth story. | ~$500 (+32%) |
| Base (our anchor) | Estimates roughly hit — FY26E adj. EPS ~$14.50 (mid of guidance), FY27E $16.46; a steady high-quality compounder digesting M&A earns a ~24× forward multiple. | ~$400 (+5%) |
| Bear | Integration friction, margin dilution from lower-margin diagnostics, China/instrument softness, or leverage overhang; FY27E EPS misses toward ~$15 and the multiple de-rates to ~20×. | ~$300 (−21%) |
Synthos fair value = the base case, ~$400 (+5%), with the full $300–$500 span as the honest range. This sits essentially on top of the Street's $395 consensus — we do not see an information edge here that would justify a materially different anchor, which is itself the tell that this is a Watch. This is a tracked call — the Forecaster Scorecard grades it once it matures.
4. Exponential Potential
Synthos separates compounders (durable high returns on capital) from exponentials (accelerating, multi-baggers-from-here). WAT is a quality compounder with limited exponential character:
- Forward growth: on estimates, revenue CAGR FY26E→FY30E is only ~6.8% ($6.44B → $8.40B) and EPS CAGR ~10.2% ($14.53 → $21.42) — solid, but not exponential. The near-term revenue doubling is the one-time effect of consolidating the acquired BD units, not an organic acceleration.
- Acceleration (2nd derivative) is negative. Management's own guidance tells the story: Q1'26 adjusted EPS grew +20% YoY, but full-year 2026 adjusted-EPS guidance is only +10-11%, and Q2'26 guidance is flat to +3.4%. Organic constant-currency growth is guided at just 6.5-8.0%. The growth rate is decelerating, not speeding up. Per our flagship philosophy we hunt forward next-exponentials with accelerating growth — WAT is the opposite profile.
- Room to run: the analytical-instruments and lab-diagnostics TAM is large but mature and contested (Agilent, Thermo, Danaher, Bruker, Sciex). At ~$31B market cap with mid-single-digit organic growth, a 3-5× from here is not a credible base case.
- Reinvestment runway: capex is modest (~3.3% of revenue) and the real "reinvestment" was the BD acquisition — a bet on diagnostics reach, not an organic exponential engine.
Exponential Potential: Low-Moderate (4/10). Own WAT, if at all, for durable ~10% earnings compounding and a fortress razor-blade model — not for a fast multibagger. A small accelerating name with these margins would score 8+; a mature ~$31B instruments compounder digesting M&A earns a 4.
5. Financials (real numbers — FMP annual/quarterly)
- Revenue: FY25 $3.17B, +7.0% (FY24 $2.96B, roughly flat on FY23 $2.96B). The pre-deal business was a low-single-digit grower recovering from a soft instrument cycle. FY26 will roughly double to a guided ~$6.4B as BD units consolidate.
- Quarterly trajectory (the deal inflection): organic quarters ran Q1'25 $662M → Q2 $771M → Q3 $800M → Q4 $932M; then Q1'26 reported $1.267B — of which $747M organic (+13% reported YoY) and $520M from the acquired BD businesses (owned-period). The jump is M&A, not organic.
- Margins: gross 55% TTM (a step down from the pre-deal ~59-60% as lower-margin diagnostics mix in), EBITDA margin ~24.5% TTM, net margin ~11.9% TTM (depressed by acquisition purchase-accounting charges — GAAP Q1'26 was a ($0.87) loss purely from amortization of acquired intangibles and inventory step-up; adjusted EPS was +20% to $2.70).
- Earnings: FY25 GAAP net income $643M, EPS $10.80 (adj. higher). Note GAAP EPS will be noisy for several quarters as purchase-accounting charges flow through — use adjusted EPS and free cash flow to track the real business.
- Cash flow: FY25 operating CF $653M, capex −$113M, FCF $540M — a genuine cash machine (FCF/net income >80% pre-deal). Watch whether integration costs dent this in 2026.
- Balance sheet: pre-deal FY25 net debt was only $903M (~0.9× EBITDA) — pristine. Post-deal leverage is materially higher: the TTM net-debt/EBITDA metric of 5.5× reflects transaction financing; management's plan is to delever from FCF. This is the single most important balance-sheet item to monitor.
6. Valuation — priced in or room?
WAT is not cheap and not egregious — it is roughly fair. Trailing GAAP is optically rich (48× TTM EPS, EV/S ~7.9×, EV/EBITDA ~32× on the transaction-distorted TTM), but the forward picture normalizes as the acquired earnings annualize and purchase-accounting noise fades:
- Forward P/E on consensus/guidance: ~26× (FY26E, EPS ~$14.53) → ~23× (FY27E, $16.46) → ~18× (FY30E, $21.42).
- Forward EV/EBITDA lands around ~15× on FY26E EBITDA (~$2.2B) — reasonable for a high-quality instruments compounder.
For ~10-12% forward EPS growth, a ~24-26× forward multiple is a fair, not a bargain, price — you are paying up for recurring-revenue quality but getting no discount. A reverse read: at $379 the market is pricing the deal to work and low-double-digit compounding to continue, with little embedded upside. Street targets (context): consensus $395, high $440, low $350 — our $400 base FV essentially matches consensus, and the Street's own Hold rating (12 Buy / 20 Hold / 3 Sell) corroborates the "fairly valued, wait" read. FMP's letter rating is B (P/E score a weak 1/5 — i.e. the model also flags valuation as the least attractive attribute).
7. Technicals (from the tech block)
- Trend: mild up. $379 sits above both the 50-DMA (~$348.7) and 200-DMA (~$348.0), which are essentially converged — a stock that went nowhere for a year and has only recently broken higher. MACD +6.97 (positive).
- Location: −8.1% off the 52-week high ($412.5), +36.6% off the 52-week low ($277.7); max drawdown from peak −10.7% — a moderate, not violent, trading range.
- Momentum: RSI(14) 67 — strong and approaching but not yet overbought (<70). A near-term-extended entry, not a screaming one.
- Relative strength (the tell): WAT is a laggard — +6.2% 12-mo vs SPY +20.6% and QQQ +30.3%. It has underperformed both the market and the Nasdaq over a year. The recent strength is real (+26.5% 3-mo vs SPY +13.7%), largely a re-rating on the deal, but the one-year picture is of a market underperformer just now catching a bid.
- Read: technicals are constructive but unremarkable — an early uptrend off a long base, momentum firm but stretched short-term. No technical reason to chase; a pullback toward the converged ~$348 moving averages would be a lower-risk entry for anyone who wants the name.
8. Moat & competitive position
Waters' moat is a classic razor-and-blades installed base: high-end LC/MS instruments create a long tail of high-margin, recurring consumables (columns, chemistry) and service revenue, with steep switching costs in regulated pharma QA/QC environments (revalidation is expensive, so labs stay). Service + consumables exceeding instrument revenue (§1) is the quantified proof of that stickiness. The BD acquisition extends the moat into biosciences and clinical diagnostics — adjacent, also-recurring, also-regulated markets — if integration delivers.
The competitive frame is a concentrated set of premium life-sciences-tools players. Threats: larger, better-capitalized rivals (Thermo Fisher, Danaher, Agilent), instrument-cycle cyclicality (pharma capex, China), and execution risk on a large, complex acquisition.
Peer set (FMP-provided, market cap): Mettler-Toledo $26B (the closest instruments comp), West Pharmaceutical $26B, Illumina $29B, DexCom $27B, Quest Diagnostics $24B, Labcorp $24B, STERIS $21B, Incyte $23B, Medpace $16B, Zimmer Biomet $17B. WAT trades at a premium multiple to most of this group — consistent with its recurring-revenue quality but leaving little valuation cushion.
9. Management, capital allocation & guidance
- Capital allocation: the defining decision is the BD Biosciences & Diagnostic Solutions acquisition (closed 2026-02-09) — a bold, ~$17.5B, revenue-doubling, debt-and-stock-funded bet on diagnostics reach. This is a bet-the-strategy move: it adds growth and end-market diversification but consumes the pristine pre-deal balance sheet and introduces multi-year integration risk. Modest buybacks and no dividend (yield 0%); capital is going to the deal and deleveraging.
- Insider activity: the recent window is mostly routine — director stock awards (Knight, Jiang) and executive F-InKind tax-withholding dispositions (CFO Chaubal, SVPs Carpio/Bennett), which are not discretionary sells. One mild positive: director Wei Jiang bought 500 shares at $289.46 on 2026-03-16 (an open-market P-Purchase) — a small but genuine insider buy near the lows. No alarming cluster of discretionary selling.
- Management's own guidance — the earnings-release track (half-weighted; they talk their own book). Guidance was available and reads like a real earnings release (SEC 8-K Item 2.02, filed 2026-05-05). In their own words, management raised FY26 guidance after a Q1 beat:
- Full-year 2026: total reported revenue $6.405–6.455B; organic constant-currency growth 6.5–8.0% (raised); acquired-business reported revenue ~$3.035B; adjusted EPS $14.40–14.60 (+10–11% YoY).
- Q2 2026: total reported revenue $1.616–1.631B; adjusted EPS $2.95–3.05 (flat to +3.4% YoY).
- CEO Udit Batra framed Q1 as "an excellent first quarter as a combined company," citing "significant improvement in growth rates versus pre-close trends" in the acquired divisions and "exceptional momentum" in organic growth.
- Honest weighting: this is management's self-interested framing, half-weighted by design. The signal we take is (a) the deal's early integration is tracking to/ahead of plan, and (b) even so, headline adjusted-EPS growth decelerates to ~10-11% — corroborating the Growth-Quality and Exponential scores above.
10. Catalysts & what to watch
- Next earnings: 2026-08-04 (Q2'26; Street EPS $3.00, revenue ~$1.62B). First clean sequential read on BD integration and whether management holds/raises the FY26 guide.
- Integration milestones: revenue synergies (guidance embeds $15M FY26 organic + $35M acquired-business synergies), margin trajectory as diagnostics mix settles, and deleveraging progress.
- Instrument replacement cycle & China: high-single-digit instrument growth was a Q1 bright spot — watch for durability vs a renewed pharma/China capex pause.
- Gross-margin normalization: whether the blended margin stabilizes above ~55% or drifts lower as diagnostics scales.
- GAAP-to-adjusted convergence: purchase-accounting charges (amortization, inventory step-up) should ease over coming quarters — track adjusted EPS and FCF as the true signal.
Thesis tripwires (what would change the call): two quarters of integration-driven margin misses; leverage failing to trend down; organic constant-currency growth slipping below ~5%; or a cut to the FY26 adjusted-EPS guide. Any of these pushes toward Avoid; a clean integration with sustained double-digit adjusted-EPS growth and visible deleveraging could push toward Buy — Tactical.
11. Key risks
- Integration risk (structural, near-term): absorbing ~$17.5B of BD businesses without margin, culture or systems damage is the whole story for the next 2-3 years. Large tools/diagnostics integrations frequently disappoint.
- Leverage: the pristine pre-deal balance sheet is gone; post-deal net-debt/EBITDA is elevated (transaction-loaded TTM ~5.5×). Deleveraging depends on FCF holding up during integration.
- Valuation / de-rating: 48× trailing, ~26× forward, premium to peers, and a Hold-rated Street — little cushion if execution slips.
- Cyclicality & China: instrument demand tracks pharma/biotech and academic capex and Chinese stimulus; ~33% APAC revenue exposure.
- Margin dilution: the acquired diagnostics business carries lower gross margins than the legacy consumables razor-blade base.
- Zero expert corroboration: unlike our conviction names, there is no independent expert panel in the KB to cross-check this thesis — epistemic confidence is lower, reflected in the Low conviction rating.
12. Verdict, position sizing & monitoring
Watch. Waters is a genuinely high-quality, wide-moat razor-blade franchise, and the BD acquisition is a credible bet to add growth and diagnostics reach. But three things hold it at Watch rather than Buy: (1) at ~26× forward for ~10-12% EPS growth the stock is fairly, not attractively, valued — our $400 base FV sits right on the $395 Street consensus; (2) the near-term story is integration and deleveraging risk, not organic acceleration, with adjusted-EPS growth decelerating to ~10-11%; and (3) there is no expert coverage to raise conviction above the fundamentals. This is a name to own for quality at the right price, and today's price offers no edge.
- Sizing: if owned, a small ~1-2% quality-cyclical position; there is no urgency to add here. A pullback toward the ~$348 moving-average cluster, or a clean Q2 integration print, would improve the risk/reward.
- Monitoring: re-underwrite on the §10 tripwires; formal re-score at the 2026-08-04 print. This verdict is logged as a tracked Synthos call as of 2026-07-03 at $379.29.
- Single biggest risk: integrating the BD Biosciences & Diagnostic Solutions acquisition without margin or leverage damage — the whole near-term verdict hinges on it.
Provenance & disclosures
- Traceability: 0 KB claims, breadth 0 — there is no expert coverage for WAT in the Synthos knowledge base, so no
claim_ids are cited. This note is explicitly fundamentals-, quant- and guidance-driven, and the Low conviction rating reflects that lower epistemic confidence. Fabricated conviction is structurally impossible (claim-ID reconciliation) and none is asserted here. - Data as-of: fundamentals 2026-04-04 (Q1'26) · estimates & prices 2026-07-03 · no expert claims. Forward figures are analyst consensus (FMP) or management guidance, labeled as estimates.
- Market-cap note: the FMP quote's $24.7B market cap uses the pre-deal ~59.5M share count; the correct post-BD figure is ~$31B on ~82.1M shares (per the Q1'26 10-Q weighted-average diluted count). Valuation multiples above use the corrected figure.
- Management caveat: WAT management guidance (SEC 8-K 2026-05-05) is management's own book, half-weighted by design.
- Not investment advice. Independent research, educational and informational only, never personalized. Hypothetical/forward figures are labeled; the only performance numbers Synthos will headline are the live, real-money Flagship's.
- Version: 2026-07-03. Prior versions available via the deep-dive version dropdown ("based on the info at the time").